arrow
D

David J. Kwiatkowski

brigham and women s hospital
H指数:135
被引数:8.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer

曲妥珠单抗德鲁克替康在晚期乳腺癌中的分子与临床疗效洞察

2025-12-040
PRE
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

YAP/TEAD抑制剂VT3989在实体瘤中的研究:一项1/2期临床试验

2025-10-190
PRE
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA
Vigabatrin-associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex

结节性硬化症婴儿的Vigabatrin相关脑磁共振成像异常和临床症状

2024-12-060
PRE
Integrating artificial intelligence (AI)-based lymphocytic infiltration assessment in early stage NSCLC: A sub-study of the TNM-I trial

整合基于人工智能(AI)的淋巴细胞浸润评估在早期非小细胞肺癌中的应用:TNM-I试验的子研究

2024-09-010
PRE
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (vol 23, pg 313, 2018)

肾细胞癌的癌症基因组图谱综合分子特征 (第23卷,313页,2018)

2024-04-010
OA
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group

结节性硬化症肾脏受累的临床实践建议: 常染色体显性结构性肾脏疾病ERKNet工作组和ERA基因和肾脏工作组的共识声明

2024-03-056
OA
Biomarker benchmarking across ancestral populations

跨祖先人群的生物标志物基准

2023-12-010
PRE
Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years
2023-11-233
OAAI
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (vol 28, 2155, 2022)
2023-10-100
OAAI
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial

基于机器学习的免疫表型与可切除NSCLC中STK11/KEAP1共突变和预后相关: tnm-i试验的子研究

2023-07-011
OAAI